Geographic Atrophy clinical trials at UC Health
4 research studies open to eligible people
A Study Assessing the Safety, Tolerability, and Efficacy of RO7171009 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
open to eligible people ages 60 years and up
This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of RO7171009 administered every 4 weeks (Q4W) or every 8 weeks (Q8W) for approximately 76 weeks in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) compared with sham control.
at UCLA
Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD
open to eligible people ages 55 years and up
The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD).
at UC Davis UC Irvine UCLA UCSD UCSF
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
open to eligible people ages 60 years and up
This is a 30-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
at UC Irvine
This is a 30-month, Phase III, Multicenter, Randomized, Double-masked, Sham-injection Controlled Study to Assess the Efficacy and Safety of Multiple IVT Injections of APL-2 in Subjects With GA Secondary to AMD
open to eligible people ages 60 years and up
This is a 30-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
at UCLA UCSD
Last updated: